Jacqualyn Fouse - Apr 8, 2022 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role
Chief Executive Officer, Director
Signature
/s/ William Cook, as Attorney-in-fact for Jacqualyn Fouse
Stock symbol
AGIO
Transactions as of
Apr 8, 2022
Transactions value $
$0
Form type
4
Date filed
4/12/2022, 04:01 PM
Previous filing
Apr 4, 2022
Next filing
Jun 17, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGIO Stock options (right to buy) Award $0 +170K $0.00 170K Apr 8, 2022 Common stock 170K $29.46 Direct F1
transaction AGIO Restricted stock units Award $0 +47.8K $0.00 47.8K Apr 8, 2022 Common stock 47.8K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on April 8, 2022. The shares underlying this option vest as to 25% of the underlying shares on April 8, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F3 The restricted stock units were granted on April 8, 2022. Beginning on April 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments.